VolitionRx Unveils Innovative Lateral Flow Test for Nucleosome Quantification at Point-of-Care Settings

On July 8, 2025, VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering company in epigenetics, announced a significant advancement in medical diagnostics: the successful development of a lateral flow test that enables rapid quantification of nucleosomes in whole venous blood. This test, part of the SUMMIT program, provides timely results within minutes and is designed for use in a variety of clinical settings, including doctors' offices, emergency departments, and intensive care units.

The blind study that demonstrated this groundbreaking technology involved blood samples taken from 25 patients admitted to the hospital. Results showed a strong correlation with an established automated laboratory assay known as the Nu.Q® nucleosome assay developed by Volition. This technological innovation has the potential to streamline the early detection of immune disruptions which could lead to critical conditions such as sepsis.

Mr. Gael Forterre, Volition’s Chief Commercial Officer, emphasized the clinical implications of this advancement. He stated, "The ability to rapidly identify high-risk patients through the quantification of nucleosome levels using a simple lateral flow device could facilitate quicker clinical decision-making and improve patient outcomes significantly."

The introduction of this test is poised to make a substantial impact, particularly in regions where access to robust laboratory infrastructure is lacking. Forterre indicated this technology could redefine approaches to diseases where urgent care is critical, such as sepsis, enhancing the quality of care in environments that may not have access to conventional laboratory capabilities.

A groundbreaking aspect of this test is its qualitative approach: rather than merely providing a positive or negative result, it offers a numerical readout that aids in informed clinical decisions. This could potentially revolutionize patient care by allowing healthcare providers to assess patients on-site, thus reducing delays in necessary treatment.

Looking ahead, the SUMMIT program aims to further develop this technology to utilize capillary blood for the test. The ultimate goal is to create a convenient finger-prick test that can be used for additional diagnosis of various conditions.

About SUMMIT and Lateral Flow Tests

The SUMMIT initiative is specifically focused on addressing unmet needs in disease monitoring, particularly sepsis, through the development of rapid testing technology. The project is partially financed by the Walloon Region, showcasing collaboration between different sectors to enhance healthcare diagnostics.

Lateral flow tests, which the Nu.Q® nucleosome test employs, have a significant history. The first commercial LFT was the Clearblue pregnancy test introduced in the late 1980s. In recent years, lateral flow tests gained widespread recognition during the COVID-19 pandemic, demonstrating their efficiency at swiftly detecting specific molecules in diverse biological samples.

About Volition and its Competitive Edge

Volition is committed to advancing the science of epigenetics, focusing on enhancing patients' lives through earlier disease detection and comprehensive monitoring. The company is dedicated to developing straightforward, cost-effective blood tests for various diseases, including certain cancers and conditions related to NETosis, including sepsis. Their Nu.Q® nucleosome assay is already CE Mark approved and is accessible in 27 countries across Europe, reflecting its reliability and acceptance in the medical community.

With a research background grounded in Belgium, Volition is expanding its innovation capacity through an operational base in the U.S. and an office in London, ensuring its technology reaches a global audience. As the landscape of medical diagnostics continues to evolve, VolitionRx stands at the forefront, pioneering solutions aimed at improving health outcomes for patients across the globe.

In conclusion, the advent of this lateral flow test represents a remarkable leap forward in medical diagnostics. With its rapid, quantitative analysis capabilities and potential for bedside application, it promises to enhance early detection and treatment of critical conditions, truly embodying the future of point-of-care testing.